Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis

被引：0
作者：
Schiff, Michael [1 ]
Sadowski, Peter [2 ]
机构：
[1] Univ Colorado, Div Rheumatol, Denver, CO 80202 USA
[2] Antares Pharma Inc, Minneapolis, MN USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3194
引用
收藏
页数：3
相关论文
共 2 条
  • [1] Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
    Schiff, Michael H.
    Jaffe, Jonathan S.
    Freundlich, Bruce
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1549 - 1551
  • [2] 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
    Singh, Jasvinder A.
    Furst, Daniel E.
    Bharat, Aseem
    Curtis, Jeffrey R.
    Kavanaugh, Arthur F.
    Kremer, Joel M.
    Moreland, Larry W.
    O'Dell, James
    Winthrop, Kevin L.
    Beukelman, Timothy
    Bridges, S. Louis, Jr.
    Chatham, W. Winn
    Paulus, Harold E.
    Suarez-Almazor, Maria
    Bombardier, Claire
    Dougados, Maxime
    Khanna, Dinesh
    King, Charles M.
    Leong, Amye L.
    Matteson, Eric L.
    Schousboe, John T.
    Moynihan, Eileen
    Kolba, Karen S.
    Jain, Archana
    Volkmann, Elizabeth R.
    Agrawal, Harsh
    Bae, Sangmee
    Mudano, Amy S.
    Patkar, Nivedita M.
    Saag, Kenneth G.
    [J]. ARTHRITIS CARE & RESEARCH, 2012, 64 (05) : 625 - 639
1